#Insurancepolicy

A groundbreaking, nationwide study led by Washington University in St. Louis has found that vagus nerve stimulation—a procedure originally developed to manage severe epilepsy—could offer significant relief for people suffering from treatment-resistant depression (TRD), a condition that does not improve with conventional antidepressant medications. This large-scale research, one of the most comprehensive ever conducted on the subject, could influence insurance coverage policies and potentially change how doctors in Thailand and worldwide approach some of the hardest-to-treat cases of depression (St. Louis Post-Dispatch).

A nationwide study led by a major U.S. university suggests that vagus nerve stimulation (VNS) may provide meaningful relief for those with treatment-resistant depression (TRD). VNS is a surgical option originally developed for epilepsy, now explored as a potential therapy for patients who do not respond to conventional antidepressants. The findings, one of the most comprehensive to date, could influence insurance coverage decisions and reshape approaches to the toughest depression cases worldwide, including in Thailand.